Cardiology 🤝 Rheumatology #Abstract0611 highlights Subclinical atherosclerosis (carotid plaque > 1.5 mm) associated with ↑ risk of CV events in SLE longitudinal cohort @RheumNow #ACR24 https://t.co/jLLYNOfFZ2

• https://x.com/AkhilSoodMD/status/1857812622797578650/photo/1

Moderating a great talk about POTS - great slide & nice presentation technique Dr. Adler flashed a screen of the ROS for pts w/POTs, overwhelming as expected… then overlaid common causes and phenotypes - really like this as a framework! #ACR24 @RheumNow https://t.co/mCmtygxxv4

• https://x.com/EBRheum/status/1857812262070714500/photo/1

🚨Therapeutic target in PsO? Abst#0067 from Cleveland Clinic evaluated pts w/ PsO at high risk for PsA (HR-PsO). - HR-PsO: ⬆️percentage in migratory dendritic cells with elevated expression of CXCR4. - Migratory effect ⬇️ after selective CXCR4 inhibitor. #ACR24 @ElaineHusniMD… https://t.co/nVoAThUxi1 https://t.co/8d1K3nkttI

• https://x.com/i/web/status/1857812119649136924
• https://x.com/AdelaCastro222/status/1857812119649136924/photo/1
• https://x.com/AdelaCastro222/status/1857812119649136924/photo/1

Implementing an automated inflammatory back pain screening tool in community rheumatology practices significantly enhances the identification of axial spondyloarthritis. With 14.3% of positive screenings leading to diagnosis. Another innovation that may help with the rapid… https://t.co/qSwryK22uj

• https://x.com/i/web/status/1857812119326183889

#0456📱 Digital Health & RA ePROs 💻Rx response in 150 RA patients using ePROs & actigraphy 🔍Actigraphy slightly improved accuracy (86% precision, 83% v. 75% recall with ePROs alone) 💡Passive actigraphy can help classify response &⬇️ ePROs, patient burden. #ACR24 @RheumNow

🤨To cycle or not to cycle TNFi. Abst#0585 studied pts with PsA and axSpA with primary TNFi failure: -Switching to IL17Ai may benefit phGA for arthritis and psoriasis in PsA pts and fatigue in axSpA pts. @AlexisOgdie #ACR24 @RheumNow https://t.co/Jc0cdmrVhI

• https://x.com/AdelaCastro222/status/1857810860795638038/photo/1

Can PROs help identify high-risk #SLE patients? #Abstract0655 from the FORWARD registry shows higher SLAQ scores (including flares) and RDCI are linked to increased hospitalization risk. @RheumNow #ACR24

Abstract 0587: Among PsA patients (bDMARD-naive & TNF non-responders) treated with Bimekizumab, better disease control was linked to improved work productivity, including ↓ work impairment, ↓ presenteeism, and ↓ activity impairment. #ACR24 @RheumNow https://t.co/sZBjJ9lk39

• https://x.com/AkhilSoodMD/status/1857810357684941164/photo/1

TAPIR study of continuing vs stopping steroids in ANCA vasculitis in remission. Relapse at month 6 in 16% vs 4%. OR 4.22, but low rate in either group. If treated Rituximab, no difference! Merkel et al. @RheumNow #ACR24 Abstr#0774 #ACRbest https://t.co/pKa4U5L2fW https://t.co/MjzE14SeGi

• A Multicenter, Randomized, Controlled Trial to Evaluate the Effects of Low-dose…
• https://x.com/RichardPAConway/status/1857810106181718508/photo/1

Happening now: 16S18 Into the Weeds: Cannabis in Rheum @EleniTiniakou @BharatKumarMD Do you discuss marijuana with your patients? @RheumNow #ACR24

Ashgar et al. Metformin reduces risk of TKR in T2DM with OA in meta-analysis. RR 0.59 @RheumNow #ACR24 Abstr#0029 https://t.co/OhqTJZQwKX https://t.co/RTQUjE6lLy

• Effect of Metformin on the Incidence of Total Knee Replacement: A Systematic Re…
• https://x.com/RichardPAConway/status/1857809351450173642/photo/1

Abstr#0647 Toronto Lupus Clinic finds pericarditis in 20% of #SLE inception cohort, often with skin, heme, MSK, & renal involvement. Linked to younger age, White race, +SSB, & lower ACR/EULAR scores - Tx: GC, HCQ, AZA @RheumNow #ACR24

Abstract #0614 What is the impact of Lupus on my quality of life? Consider using Lupus Impact Tracker (https://t.co/fJQe2uHicM) - high dose GC, comorbidities, and not actively working associated with worse impact on QoL - HCQ shows benefit @RheumNow #ACR24

• Lupus symptoms impact tracker | Lupus Foundation of America

#0477 🌍 Global prevalence of RA-ILD ➡️21.38% (95% CI 0.15 - 0.29),33 studies, n=14,281 🔬 Higher RA-ILD risk in smokers, low-income regions, DMARD use. ⛔️Wide CI = heterogeneity main limitation 💡 Screening & lifestyle changes key for high-risk groups. #ACR24 @RheumNow

Harnessing power of AI in Rheumatology. Strengths and weaknesses of AI will need to be assessed. Amanda Nelson shares the limitation of AI @RheumNow #ACR24 https://t.co/G8FNVco7Qp

• https://x.com/synovialjoints/status/1857808573465530859/photo/1